352 related articles for article (PubMed ID: 31416160)
21. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
Jeanne M; Lallemand-Breitenbach V; Ferhi O; Koken M; Le Bras M; Duffort S; Peres L; Berthier C; Soilihi H; Raught B; de Thé H
Cancer Cell; 2010 Jul; 18(1):88-98. PubMed ID: 20609355
[TBL] [Abstract][Full Text] [Related]
22. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
23. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
24. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies.
Saitoh N; Uchimura Y; Tachibana T; Sugahara S; Saitoh H; Nakao M
Exp Cell Res; 2006 May; 312(8):1418-30. PubMed ID: 16688858
[TBL] [Abstract][Full Text] [Related]
25. Promyelocytic Leukemia Protein, a Protein at the Crossroad of Oxidative Stress and Metabolism.
Tessier S; Martin-Martin N; de Thé H; Carracedo A; Lallemand-Breitenbach V
Antioxid Redox Signal; 2017 Mar; 26(9):432-444. PubMed ID: 27758112
[TBL] [Abstract][Full Text] [Related]
26. Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions.
Wang J; Shiels C; Sasieni P; Wu PJ; Islam SA; Freemont PS; Sheer D
J Cell Biol; 2004 Feb; 164(4):515-26. PubMed ID: 14970191
[TBL] [Abstract][Full Text] [Related]
27. New Evidence of the Importance of Weak Interactions in the Formation of PML-Bodies.
Fonin AV; Silonov SA; Fefilova AS; Stepanenko OV; Gavrilova AA; Petukhov AV; Romanovich AE; Modina AL; Zueva TS; Nedelyaev EM; Pleskach NM; Kuranova ML; Kuznetsova IM; Uversky VN; Turoverov KK
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163537
[TBL] [Abstract][Full Text] [Related]
28. PML nuclear bodies and chromatin dynamics: catch me if you can!
Corpet A; Kleijwegt C; Roubille S; Juillard F; Jacquet K; Texier P; Lomonte P
Nucleic Acids Res; 2020 Dec; 48(21):11890-11912. PubMed ID: 33068409
[TBL] [Abstract][Full Text] [Related]
29. Solubility changes of promyelocytic leukemia (PML) and SUMO monomers and dynamics of PML nuclear body proteins in arsenite-treated cells.
Hirano S; Udagawa O; Kobayashi Y; Kato A
Toxicol Appl Pharmacol; 2018 Dec; 360():150-159. PubMed ID: 30292834
[TBL] [Abstract][Full Text] [Related]
30. Two-step colocalization of MORC3 with PML nuclear bodies.
Mimura Y; Takahashi K; Kawata K; Akazawa T; Inoue N
J Cell Sci; 2010 Jun; 123(Pt 12):2014-24. PubMed ID: 20501696
[TBL] [Abstract][Full Text] [Related]
31. PML plays both inimical and beneficial roles in HSV-1 replication.
Xu P; Mallon S; Roizman B
Proc Natl Acad Sci U S A; 2016 May; 113(21):E3022-8. PubMed ID: 27162364
[TBL] [Abstract][Full Text] [Related]
32. Subcellular distribution of nuclear import-defective isoforms of the promyelocytic leukemia protein.
Jul-Larsen A; Grudic A; Bjerkvig R; Bøe SO
BMC Mol Biol; 2010 Nov; 11():89. PubMed ID: 21092142
[TBL] [Abstract][Full Text] [Related]
33. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
34. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells.
Rivera OJ; Song CS; Centonze VE; Lechleiter JD; Chatterjee B; Roy AK
Mol Endocrinol; 2003 Jan; 17(1):128-40. PubMed ID: 12511612
[TBL] [Abstract][Full Text] [Related]
35. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.
Lai HK; Borden KL
Oncogene; 2000 Mar; 19(13):1623-34. PubMed ID: 10763819
[TBL] [Abstract][Full Text] [Related]
36. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies.
Borden KL
Mol Cell Biol; 2002 Aug; 22(15):5259-69. PubMed ID: 12101223
[No Abstract] [Full Text] [Related]
37. Localization and regulation of PML bodies in the adult mouse brain.
Hall MH; Magalska A; Malinowska M; Ruszczycki B; Czaban I; Patel S; Ambrożek-Latecka M; Zołocińska E; Broszkiewicz H; Parobczak K; Nair RR; Rylski M; Pawlak R; Bramham CR; Wilczyński GM
Brain Struct Funct; 2016 Jun; 221(5):2511-25. PubMed ID: 25956166
[TBL] [Abstract][Full Text] [Related]
38. Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
Hirano S; Udagawa O
PLoS One; 2022; 17(5):e0268835. PubMed ID: 35594310
[TBL] [Abstract][Full Text] [Related]
39. Emerging Role of PML Nuclear Bodies in Innate Immune Signaling.
Scherer M; Stamminger T
J Virol; 2016 Jul; 90(13):5850-5854. PubMed ID: 27053550
[TBL] [Abstract][Full Text] [Related]
40. The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body.
Boisvert FM; Kruhlak MJ; Box AK; Hendzel MJ; Bazett-Jones DP
J Cell Biol; 2001 Mar; 152(5):1099-106. PubMed ID: 11238464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
